Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma

Haihong Wang1†, Zhenyu Lin1†, Guiling Li1, Dejun Zhang1, Dandan Yu1, Qili Lin2, Jing Wang1, Ye Zhao1, Guoliang Pi3 and Tao Zhang1*

Abstract

Background: The American Joint Committee on Cancer (AJCC) and the European Neuroendocrine Tumor Society (ENETS) staging classifications are two broadly used systems for pancreatic neuroendocrine tumors. This study aims to identify the most accurate and useful tumor–node–metastasis (TNM) staging system for poorly differentiated pancreatic neuroendocrine carcinomas (pNECs).

Methods: An analysis was performed to evaluate the application of the ENETS, 7th edition (7th) AJCC and 8th edition (8th) AJCC staging classifications using the Surveillance, Epidemiology, and End Results (SEER) registry (N = 568 patients), and a modified system based on the analysis of the 7th AJCC classification was proposed.

Results: In multivariable analyses, only the 7th AJCC staging system allocated patients into four different risk groups, although there was no significant difference. We modified the staging classification by maintaining the T and M definitions of the 7th AJCC staging and adopting new staging definitions. An increased hazard ratio (HR) of death was also observed from class I to class IV for the modified 7th (m7th) staging system (compared with stage I disease; HR for stage II = 1.23, 95% confidence interval (CI) = 0.73–2.06, P = 0.44; HR for stage III = 2.20, 95% CI = 1.06–4.56, P = 0.03; HR for stage IV = 4.95, 95% CI = 3.20–7.65, P < 0.001). The concordance index (C-index) was higher for local disease with the m7th AJCC staging system than with the 7th AJCC staging system.

Conclusions: The m7th AJCC staging system for pNECs proposed in this study provides improvements and may be assessed for potential adoption in the next edition.

Keywords: Neoplasm staging, SEER program, Pancreatic neuroendocrine carcinoma, Poorly differentiated

Background

Pancreatic neuroendocrine tumor is a rare malignancy with great heterogeneity, which presented with variable biologic behavior ranging from benign or indolent to frankly malignant or aggressive [1]. Its incidence has been increasing sharply in recent years, partly due to the increased application of computed tomographic scans and endoscopic technologies [2, 3]. According to tumor morphology and markers of proliferation, neuroendocrine neoplasms of the pancreas (pNENs) are divided into well-differentiated pancreatic neuroendocrine tumors (pNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs) [4]. It is reported that pNECs only account for about 15% of pNENs [5–7], and several studies have shown that the clinicopathological features, prognosis and gene expression between pNECs and pNETs are completely different [1, 8–11]. Thus, due to their rarity and heterogeneity, pNECs have not been well studied, and standard staging tools have been lacking. Therefore, a staging system that can accurately provide prognostic information and stratify patients by risk is urgently needed.

TNM staging, an accurate and simple instrument for prognosis assessment and patient management at diagnosis for physicians, is the most frequently used...
indicator of outcomes for malignancies. Currently, there are two major different TNM-based staging systems for pNENs in use. A TNM staging system specially for pNENs was first proposed in the year 2006 by the ENETS [12]. This staging system was validated to risk stratify patients and discriminate among prognostic groups for pNENs by several studies [2, 13–19]. However, the vast majority of participants used to inform the ENETS staging classification were diagnosed with pNETs. Thus, the ENETS staging system has been recommended by the National Comprehensive Cancer Network guidelines for pNETs. In 2010, the 7th AJCC staging system first staged pNENs and employed the same staging system as they used for exocrine pancreas malignancies [20–22]. The system was also validated in several independent series for pNENs [2, 13, 23]. More recently, the 8th AJCC staging system on pancreatic ductal adenocarcinoma, which was released in October, 2016, has been recommended to replace the old version (the 7th AJCC) [24]. The tumor definitions and derived stages of the ENETS, 7th AJCC and 8th AJCC staging systems differ greatly (Supplementary Table 1). Moreover, the two AJCC staging systems are the same as for the ductal adenocarcinoma and not meant for pNECs. Therefore, the question regarding the suitable staging system specially for pNECs remain unanswered.

The majority of the research in the literature consists of small studies focusing on a few single aspects of the disease or larger studies where only a few cases of pNECs are included in a larger pNEN-cohort. This study was performed to analyses the performance of the ENETS, 7th and 8th AJCC staging classifications when a large series of pNECs were used, and test a new modified staging classification that would address the weaknesses associated with 7th staging classifications system.

Methods

Patients and data collection

The data used in our study were retrieved between 1973 and 2015 from the SEER database of the US National Cancer Institute. Primary site labels “C25.0-C25.4” and “C25.7-C25.9” were used. Eligible patients were those diagnosed with pathologically confirmed poorly differentiated or undifferentiated pNENs, who were identified using the following International Classification of Diseases for Oncology (3rd edition) codes: 8150/3, 8151/3, 8152/3, 8153/3, 8155/3, 8156/3, 8157/3, 8240/3, 8241/3, 8242/3, 8243/3, 8246/3, and 8249/3. Patient demographics (race, sex, age at diagnosis, year of diagnosis, survival months, SEER cause-specific death classification) were included. TNM information was retrieved based on the following codes: derived AJCC stage group (7th edition; 2010+), derived AJCC stage group(6th edition; 2004+), collaborative stage (CS) tumor size (2004+), CS extension (2004+), CS lymph nodes (2004+), CS metastases at dx (2004+), regional lymph nodes examined (1988+), regional node positive (1988+), derived SEER summary stage 1977 (1995–2000), SEER summary stage 2000 (2001–2003), Summary stage 2000 (1998+), extent of disease (EOD) 10 - nodes (1988–2003), EOD 10 - extent (1988–2003), and EOD 10 - size (1988–2003). We excluded those who had: unknown follow-up information, unknown cancer stage at diagnosis and any other primary tumors. The patients with unknown extent of tumor or lymph node status were included in our study if they had distant metastases.

Statistical analysis

Several different statistical methods were applied to compare different staging schemes. We used Kaplan–Meier method to estimate tumor-related death-free survival. Patients dying from causes other than their cancer were censored at their date of death. Multivariate analysis of each staging classification, controlling for race, sex, age and tumor location was performed using cox proportional hazards regression. HRs and 95% CIs were calculated. C-indices were calculated to evaluate the discriminatory powers of the two staging systems between the 7th AJCC and the m7th AJCC staging systems for pNECs. A C-index of 1 represents perfect discrimination, and a C-index of 0.5 means agreement by chance alone [25]. Analyses were performed using SPSS version 22.0 and R version 3.5.1. All results are from 2-sided hypothesis tests with the significance level set to 0.05.

Results

Patients characteristics

A total of 644 eligible patients with pathologically confirmed pNECs were identified from the SEER database. And 75 cases were excluded for unknown cancer stage at diagnosis, 1 for unknown follow-up information. In total, 568 patients were included in the study. Table 1 shows frequency distributions of selected characteristics for the full study cohort. The median age at diagnosis was 63.0 years (mean 62.0 years). Male patients account for a slightly higher proportion than female patients (a male to female ratio of 1.4:1.0). More than three quarters of the patients were white. In addition, 41.5% of the patients had tumors located at the head of the pancreas. A total of 418 patients died of their cancer. The estimated median overall survival (OS) was 10.0 months.

ENETS staging classification and survival

According to the ENETS staging classification, only 1.2% (7 of 568) of patients had stage I tumors and 6.0% (34 of 568) of patients had stage II tumors (Table 2). Overlap was noticed for the ENETS classification of stage II and
III disease (Fig. 1a-b). In addition, median OS uniformly decreased from class I to II, was longer in class III, and decreased further in class IV. The median OS for stage I, II, III and IV were 90.0, 40.0, 48.0 and 7.0 months, respectively (Table 2). Compared with stage I disease, the HR of stage II was comparable to that of stage III (stage Table 1 Baseline Clinicopathologic Characteristics (Continued)

| Characteristic | N = 568 |  |
|---------------|---------|---|
| Age, years |
| < 60 | 231 | 40.7 |
| ≥ 60 | 337 | 59.3 |
| Sex |
| Male | 335 | 59.0 |
| Female | 233 | 41.0 |
| Race |
| White | 443 | 78.0 |
| Black | 67 | 11.8 |
| Other | 58 | 10.2 |
| Year of diagnosis |
| 1988–1997 | 60 | 10.6 |
| 1998–2007 | 187 | 32.9 |
| 2008–2015 | 321 | 56.5 |
| Location |
| Head | 236 | 41.5 |
| Body and tail | 179 | 31.5 |
| Other* | 153 | 27.0 |
| ENETS stage |
| I | 7 | 1.2 |
| II | 34 | 6.0 |
| IIA | 15 | 2.6 |
| IIB | 19 | 3.4 |
| III | 113 | 19.9 |
| IIIA | 25 | 4.4 |
| IIIB | 88 | 15.5 |
| IV | 414 | 72.9 |
| 8th AJCC stage |
| I | 35 | 6.2 |
| IA | 8 | 1.4 |
| IB | 27 | 4.8 |
| II | 78 | 13.7 |
| IIA | 27 | 4.8 |
| IIB | 51 | 8.9 |
| III | 41 | 7.2 |
| IV | 414 | 72.9 |
| 7th AJCC stage |
| I | 33 | 5.8 |
| IA | 8 | 1.4 |
| IB | 25 | 4.4 |
| II | 102 | 18.0 |
| IIA | 23 | 4.1 |
| IIB | 79 | 13.9 |

*Other location included overlapping lesion of pancreas and other specified parts of pancreas

III disease (Fig. 1a-b). In addition, median OS uniformly decreased from class I to II, was longer in class III, and decreased further in class IV. The median OS for stage I, II, III and IV were 90.0, 40.0, 48.0 and 7.0 months, respectively (Table 2). Compared with stage I disease, the HR of stage II was comparable to that of stage III (stage Table 2 Univariate Analyses of tumor-related death among 568 patients using the ENETS, 8th AJCC, 7th AJCC and m7th AJCC staging systems including four tumor stages for pNECs

| TNM staging systems | Median OS (months) | HR (95%CI) | P |
|---------------------|--------------------|------------|---|
| ENETS |
| I | 90.0 | 1 |
| II | 40.0 | 3.28 (0.77–13.98) | 0.11 |
| III | 48.0 | 2.22 (0.54–9.13) | 0.27 |
| IV | 7.0 | 8.92 (2.21–35.92) | 0.002 |
| 8th AJCC |
| I | 62.0 | 1 |
| II | 138.0 | 0.70 (0.38–1.26) | 0.23 |
| III | 15.0 | 1.73 (0.93–3.21) | 0.08 |
| IV | 7.0 | 3.70 (2.26–6.06) | < 0.001 |
| 7th AJCC |
| I | 90.0 | 1 |
| II | 40.0 | 1.08 (0.60–1.93) | 0.79 |
| III | 13.0 | 2.14 (0.98–4.67) | 0.06 |
| IV | 7.0 | 4.36 (2.58–7.36) | < 0.001 |
| m7th AJCC |
| I | 90 | 1 |
| II | 31 | 1.24 (0.74–2.07) | 0.41 |
| III | 13 | 2.31 (1.12–4.75) | 0.02 |
| IV | 7 | 4.70 (3.05–7.24) | < 0.001 |

Abbreviations: AJCC American Joint Committee on Cancer; ENETS European Neuroendocrine Tumor Society; m7th AJCC modified 7th AJCC; pNECs poorly differentiated pancreatic neuroendocrine carcinomas; OS overall survival; HR hazard ratio; CI confidence interval
II and III HRs, 3.27 and 2.23, respectively) by multivariable analyses (Table 3).

The 8th AJCC staging classification and survival

It is notable that overlap existed between the 8th AJCC classification of stage I and II disease (Fig. 1c-d). The median OS, in more detail, for stage I, II, III and IV were 62, 138, 15.0 and 7.0 months, respectively (Table 2). No statistical significance was observed for HR between stage I and stage II disease by multivariable analyses (stage I served as the reference; stage II HR, 0.74; \( P = 0.32 \); Table 3).

The 7th AJCC staging classification and survival

For the 7th AJCC staging system, the median OS uniformly decreased from class I to IV (Table 2), although overlap was also noticed for the 7th AJCC classification of stage I and II disease (Fig. 2a-b). Furthermore, the median OS of the patients with the same tumor stage varied widely between the different substages. Within stage II of the current AJCC staging system, the median OS for T3N0M0 and T1-3N1M0 were 20.0 and 78.0 months, respectively. The death risk of the patients increased from stage I to IV by multivariable analyses (stage I served as the reference; stage II HR, 0.74; \( P = 0.32 \); Table 3).

Comparison of survival outcomes based on the current and modified 7th AJCC staging systems

Considering the shortcomings of the AJCC and ENETS systems cited previously, a m7th AJCC staging classification was proposed by maintaining the T and M definitions of the 7th AJCC staging system and adopting a new staging definition system. Stage IV is the same across all systems defined as disease with distant metastasis. The proportion of patients with stage I disease using the m7th AJCC staging system was higher than that of the 7th AJCC system (8.8% vs 5.8%; Table 1). Better separation of survival curves was found among stages for the m7th AJCC classification (Fig. 2c-d). There was the expected worsening in survival as tumor stage increased (Table 2). In addition, an increase in HRs was observed in the m7th AJCC staging classification by multivariable analyses, although statistically significant difference was not observed between stages I and II (compared with stage I disease; HR for stage II =1.23, 95% CI = 0.73–2.06, \( P = 0.44 \); HR for stage III =2.20, 95% CI =1.06–4.56, \( P = 0.03 \); HR for stage IV =4.95, 95% CI = 3.20–7.65, \( P < 0.001 \); Table 3).

Two types of C-indices of different staging systems for pNECs were presented in.
Table 3. Multivariate Analyses of Prognostic Factors of tumor-related death among 568 patients using the ENETS, 8th AJCC, 7th AJCC and m7th AJCC staging systems including four tumor stages for pNECs

| Characteristic | ENETS     | 8th AJCC       | 7th AJCC       | m7th AJCC      |
|---------------|-----------|----------------|----------------|---------------|
| Age, years    |           |                |                |               |
| < 60          | 1         | 1              | 1              | 1             |
| ≥ 60          | 1.63 (1.33–2.00) | < 0.001       | 1.64 (1.34–2.01) | < 0.001       | 1.66 (1.35–2.03) | < 0.001       | 1.66 (1.35–2.03) | < 0.001       |
| Sex           |           |                |                |               |
| Female        | 1         | 1              | 1              | 1             |
| Male          | 1.16 (0.95–1.41) | 0.15           | 1.16 (0.95–1.41) | 0.15          | 1.14 (0.94–1.40) | 0.18          | 1.14 (0.94–1.40) | 0.18          |
| Race          |           |                |                |               |
| Black         | 1         | 1              | 1              | 1             |
| White         | 0.65 (0.48–0.88) | 0.01          | 0.66 (0.49–0.90) | 0.01          | 0.67 (0.50–0.91) | 0.01          | 0.67 (0.50–0.91) | 0.01          |
| Other         | 0.65 (0.43–0.99) | 0.04          | 0.68 (0.45–1.04) | 0.07          | 0.68 (0.45–1.03) | 0.07          | 0.68 (0.45–1.03) | 0.07          |
| Location      |           |                |                |               |
| Body and tail | 1         | 1              | 1              | 1             |
| Head          | 1.63 (1.29–2.08) | < 0.001       | 1.61 (1.27–2.05) | < 0.001       | 1.60 (1.26–2.03) | < 0.001       | 1.60 (1.26–2.04) | < 0.001       |
| Others        | 1.67 (1.29–2.15) | < 0.001       | 1.68 (1.30–2.17) | < 0.001       | 1.67 (1.21–2.15) | < 0.001       | 1.67 (1.29–2.16) | < 0.001       |
| Stage         |           |                |                |               |
| I             | 1         | 1              | 1              | 1             |
| II            | 3.27 (0.77–14.02) | 0.11          | 0.74 (0.41–1.34) | 0.32          | 1.08 (0.60–1.94) | 0.80          | 1.23 (0.73–2.06) | 0.44          |
| III           | 2.23 (0.54–9.18) | 0.27          | 1.81 (0.97–3.38) | 0.06          | 2.06 (0.94–4.52) | 0.07          | 2.20 (1.06–4.56) | 0.03          |
| IV            | 9.59 (2.38–38.71) | 0.002         | 4.14 (2.52–6.79) | < 0.001       | 4.62 (2.73–7.83) | < 0.001       | 4.95 (3.20–7.65) | < 0.001       |

Abbreviations: AJCC American Joint Committee on Cancer; ENETS European Neuroendocrine Tumor Society; m7th AJCC modified 7th AJCC; pNECs poorly differentiated pancreatic neuroendocrine carcinomas; HR hazard ratio; CI confidence interval

Table 4. One was for local disease only, and the other was for the entire cohort. The respective C- indices using the 7th and m7th staging systems for patients with local disease (stages I–III) were 0.57 (95% CI 0.51–0.63) and 0.59 (95% CI 0.53–0.66), respectively. Also, for the entire cohort, the C- indices based on the 7th staging system (0.626, 95% CI 0.599–0.653), and the m7th staging system (0.627, 95% CI 0.600–0.654) were similar.

Discussion

Currently, there was no widely acceptable staging system for pNECs, and this was the first consolidation of a data-based process for the revision of the staging classification on pNECs. We tested three TNM staging systems to determine which was superior in terms of performance when a large series of pNECs were used.

Our data demonstrated that the 7th AJCC staging classification has better distribution of pNECs with different stages compared with the ENETS and 8th AJCC staging systems. We observed an increase in HRs by multivariable analyses and decreased median survival time from class I to IV across the 7th AJCC staging system, whereas this trend was not observed for the ENETS and 8th AJCC staging systems. However, the median OS of the patients within stage II varied widely among the different substages in the 7th AJCC system, and patients with stage IIB even had a better prognosis than that of stage IIA. The consistency of the outcomes among the substages became unclear, warranting further modifications and validation. In addition, multivariable cox regression analysis indicated that only the T definitions of the 7th AJCC could allocate patients in four risk groups for the local patients that death risk uniformly progressed from T1 to T4 (T1 served as the reference; T2 HR = 1.91, 95% CI = 0.72–5.05; T3 HR = 3.57, 95% CI = 0.89–14.28) (Supplementary Table 2), supporting the adoption of the T definitions of the 7th AJCC in our modified staging system.

Moreover, we observed that lymph node status alone was not a significant predictor of survival in univariate and multivariate analysis (Supplementary Table 3; Supplementary Table 4). As with our findings, some studies have already demonstrated the predictive value of lymph nodal status for pNENs was limited and that the nodal stage showed no distinguished differences on the
estimated cumulative survival probability [26–29]. However, given that there still existed some patients without lymph node dissection or with insufficient lymph node dissection, lymph node staging was sometimes hard to perform, and deserved to be confirmed in a relatively large sample size.

Therefore, we proposed an adjustment to the 7th AJCC staging classification by maintaining the T and M definitions but adopting a new staging definition system. The proportion of patients with stage I disease using the m7th AJCC staging system was higher than that of the 7th AJCC system (8.8% vs 5.8%). The death rates uniformly progressed from class I to IV, although there was no significant difference between stage I and stage II. Moreover, the discrimination ability for tumor-related death measured by the Harrell C statistics was slightly better for the m7th AJCC staging system relative to the 7th AJCC staging classification. Consequently, these findings suggested that the m7th AJCC staging classification was more suitable for pNECs and easier to use, and thus it should be further investigated.

The creation of new staging system based on modification of the 7th AJCC staging classification will help the stratification for patients with pNECs in the future. However, there remain uncovered situations. Although only the T definition of the 7th AJCC can allocate patients into four risk groups for the local patients without significant differences, the T staging for pNECs was challenged due to impractical and insufficient prognostic correlations for pancreatic ductal adenocarcinoma. Consequently, the definition of T needs to be further optimized according to the biological behavior of pNECs, such as the appropriate cutoff for tumor size. Even so, traditional predictors of outcome being tumor size, extent of tumor and presence of distant metastasis have not been accurate to describe the biology of pNECs. There may be more predictive of survival compared to tumor size, extension of tumor and metastatic status. Up to now, the predictors regarding the pNECs are limited. Besides the tumor stage, multivariate analyses showed that age, race and location of tumor were significantly associated with OS in our study (Supplementary Table 3; Supplementary Table 4). Also, there is no high-quality

Table 4 C-indices of Different Staging Systems for pNECs

| Staging System | Local, n = 154 | All, n = 568 |
|----------------|----------------|--------------|
| 7th AJCC       | 0.58 (0.51–0.63) | 0.626 (0.599–0.653) |
| m7th AJCC      | 0.59 (0.53–0.66) | 0.627 (0.600–0.654) |

Values in parentheses are 95% confidence intervals. Abbreviations: pNECs poorly differentiated pancreatic neuroendocrine carcinomas; AJCC American Joint Committee on Cancer; m7th AJCC modified 7th AJCC

Fig. 2 Kaplan-Meier curves of different staging classifications for patients from the SEER database. (a and b) 7th American Joint Committee on Cancer (AJCC) staging system; (c and d) modified 7th AJCC staging system.
prognostic risk assessment model for the patients with pNECs. Further efforts are necessary to focus on developing a risk assessment model, which can be offered to clinicians to assess patient prognosis, enhance patient stratification and strengthen the prognosis-based decision making.

We acknowledge several limitations. First, the study was limited by its volume of the data, which may explain the lack of significant differences between stage I and stage II using the m7th AJCC staging system. Second, since this was an opportunistic use of existing data sets, some prognostic factors reported in other studies were not considered to be adjusted for multivariate analysis because of the nonavailability of this information from SEER database, such as Ki67 staining of cancer cells and treatment-related variables. Last, although the SEER database keeps highly accurate records, incorrect coding or erroneous data are also possible. And our study was also limited by its retrospective nature, additional prospective validation will be required to evaluate the modified staging system.

Conclusions

In conclusion, the present study indicated that the 7th AJCC staging classification was superior in performance relative to the ENETS and 8th AJCC staging systems for pNECs. The 7th AJCC staging system still has room for improvement. A modified staging system is proposed by maintaining the T and M definitions of the 7th AJCC staging system. However, the modified staging system is more accurate and reliable in predicting the prognosis of pNECs. We accept that the study still has some limitations that can only be addressed by the next phase of our work, but, for now, we also believe this new staging system will be a fast and accurate prognostic assessment tool for pNECs to risk-stratify patients and guide treatment.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-6634-9.

Additional file 1 Table S1. The AJCC Staging Definitions, the ENETS Staging Definitions, and the Modified 7th AJCC Staging Definitions Staging Definitions for pNECs. Table S2. Multivariate Analyses of other predictors of tumor-related death among the local patients (N = 154) using the definitions of the ENETS, 8th AJCC, 7th AJCC staging systems for pNECs. Table S3. Univariate Analyses of other predictors of tumor-related death among 568 patients using the definitions of the ENETS, 8th AJCC, 7th AJCC staging systems for pNECs. Table S4. Multivariate Analyses of other predictors of tumor-related death among 568 patients using the definitions of the ENETS, 8th AJCC, 7th AJCC staging systems for pNECs.

Abbreviations

7th: 7th edition; 8th: 8th edition; AJCC: American Joint Committee on Cancer; CI: Confidence interval; C-Index: concordance index; CS: Collaborative Science Foundation Guiding Project (2018CFB846), Hubei Provincial Natural Science Foundation Guiding Project (2018CFB846) and The 7th Wuhan Young and Middle-aged Backbone Talent of Medical Training Project 2019 (2019 No. 87). They played an important role in the study design, collection, analysis, and interpretation of data and manuscript writing.
References

1. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, et al. Metastatic and locally advanced pancreatic neuroendocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29(17):2372–7.

2. Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American joint committee on Cancer and European neuroendocrine tumor society systems. J Clin Oncol. 2017;35(3):274–80.

3. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

4. Travis WD, Brambillia E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Daicic S, Duhiig E, Flieder DB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(5):1243–60.

5. Deletorskaya VV, Kozlov NA, Chernets GR, Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system. Klin Lab Diagn. 2013;10(48):50–10.

6. Avrdd ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blazekovszky LS, Deshpande V, Niemierko A, Allen JN, et al. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(3):e337–43.

7. You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: an institutional experience. Eur J Surg Oncol. 2009;35(7):728–33.

8. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84.

9. Kawakami K, Fuji M, Sato T. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Dis Model Mech. 2018;11(2):dmn16012.

10. Heeffeld M, Chougnet CN, Olsen IH, Rinke A, Bobath I, Crespo G, Barriuso J, Pavel M, OToole D, Walter T. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64.

11. Velayoudom-Cephise FL, Duvillard P, Foucan L, Haddou J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goede D, Debaere T, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649–57.

12. Rindi G, Koppel G, Althman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, et al. TNNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2004;444(6):391–401.

13. Rindi G, Falconi M, Kersy C, Alberante L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Dogliotti C, et al. TNNM staging of neuroendocrine tumors of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104(10):764–77.

14. Ekblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798–803.

15. Fischer L, Kleeff J, Espelios I, Hinz U, Zimmermann A, Friess H, Buchler MW. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95(5):627–35.

16. La Rosa S, Kersy C, Uccella S, Danese L, Alberante L, Sonzogni A, Dogliotti C, Capella C, Solcia E. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40(1):30–40.

17. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willichs SN, Koch M, Rocken C, Rindi G, Wiedenmann B. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113(2):256–65.

18. Zerba A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, Capitanio V, Boninsegna L, Di Carlo V. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010;105(6):1421–9.

19. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33.

20. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M. AJCC Cancer staging manual. New York: Springer; 2010.

21. Bosman FT, Camero F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010.

22. Montes HZ. TNM classification of malignant tumors, 7th edition. Int J Radiation Oncol Biol Physics. 2010;78(4):1278.

23. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kivols LD. Prognostic validity of a novel American joint committee on Cancer staging classification for pancreatic neuroendocrine tumors. J clinical oncology. 2011;29(22):3044–9.

24. Amin MB, Edge S, Greene F, Byrd DR, Royal BK, Washington MK, Gershewald JE, Compton CC, Hess KR, Sullivan DC, et al. AJCC Cancer Staging Manual (8th edition). New York: Springer; 2017.

25. Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology. 2003;229(1):3–10.

26. Yang M, Zeng L, Zhang Y, Su AP, Yue PJ, Tian BL. Surgical treatment and clinical outcome of nonfunctional pancreatic neuroendocrine tumors: a 14-year experience from one single center. Medicine. 2014;93(22):e94.

27. Franko J, Feng W, Yip L, Genoves E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointestinal Surg. 2010;14(3):541–8.

28. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19(5):903–8.

29. Yang M, Tan CL, Zhang Y, Ke NW, Zeng L, Li A, Zhang H, Xiong JJ, Guo ZH, Tian BL, et al. Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: an analysis of surgical patients from a Chinese institution. Medicine. 2016;95(28):e4213.